Cargando…

Network Pharmacology-Based Validation of Caveolin-1 as a Key Mediator of Ai Du Qing Inhibition of Drug Resistance in Breast Cancer

Chinese formulas have been paid increasing attention in cancer multidisciplinary therapy due to their multi-targets and multi-substances property. Here, we aim to investigate the anti-breast cancer and chemosensitizing function of Ai Du Qing (ADQ) formula made up of Hedyotis diffusa, Curcuma zedoari...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Neng, Yang, Bowen, Zhang, Xiaotong, Wang, Shengqi, Zheng, Yifeng, Li, Xiong, Liu, Shan, Pan, Hao, Li, Yingwei, Huang, Zhujuan, Zhang, Fengxue, Wang, Zhiyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6176282/
https://www.ncbi.nlm.nih.gov/pubmed/30333750
http://dx.doi.org/10.3389/fphar.2018.01106
_version_ 1783361669402984448
author Wang, Neng
Yang, Bowen
Zhang, Xiaotong
Wang, Shengqi
Zheng, Yifeng
Li, Xiong
Liu, Shan
Pan, Hao
Li, Yingwei
Huang, Zhujuan
Zhang, Fengxue
Wang, Zhiyu
author_facet Wang, Neng
Yang, Bowen
Zhang, Xiaotong
Wang, Shengqi
Zheng, Yifeng
Li, Xiong
Liu, Shan
Pan, Hao
Li, Yingwei
Huang, Zhujuan
Zhang, Fengxue
Wang, Zhiyu
author_sort Wang, Neng
collection PubMed
description Chinese formulas have been paid increasing attention in cancer multidisciplinary therapy due to their multi-targets and multi-substances property. Here, we aim to investigate the anti-breast cancer and chemosensitizing function of Ai Du Qing (ADQ) formula made up of Hedyotis diffusa, Curcuma zedoaria (Christm.) Rosc., Astragalus membranaceus (Fisch.) Bunge, and Glycyrrhiza uralensis Fisch. Our findings revealed that ADQ significantly inhibited cell proliferation in both parental and chemo-resistant breast cancer cells, but with little cytotoxcity effects on the normal cells. Besides, ADQ was found to facilitate the G2/M arresting and apoptosis induction effects of paclitaxel. Network pharmacology and bioinformatics analysis further demonstrated that ADQ yielded 132 candidate compounds and 297 potential targets, and shared 22 putative targets associating with breast cancer chemoresponse. Enrichment analysis and experimental validation demonstrated that ADQ might improve breast cancer chemosensitivity via inhibiting caveolin-1, which further triggered expression changes of cell cycle-related proteins p21/cyclinB1 and apoptosis-associated proteins PARP1, BAX and Bcl-2. Besides, ADQ enhanced in vivo paclitaxel chemosensitivity on breast cancer. Our study not only uncovers the novel function and mechanisms of ADQ in chemosensitizing breast cancer at least partly via targeting caveolin-1, but also sheds novel light in utilizing network pharmacology in Chinese Medicine research.
format Online
Article
Text
id pubmed-6176282
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-61762822018-10-17 Network Pharmacology-Based Validation of Caveolin-1 as a Key Mediator of Ai Du Qing Inhibition of Drug Resistance in Breast Cancer Wang, Neng Yang, Bowen Zhang, Xiaotong Wang, Shengqi Zheng, Yifeng Li, Xiong Liu, Shan Pan, Hao Li, Yingwei Huang, Zhujuan Zhang, Fengxue Wang, Zhiyu Front Pharmacol Pharmacology Chinese formulas have been paid increasing attention in cancer multidisciplinary therapy due to their multi-targets and multi-substances property. Here, we aim to investigate the anti-breast cancer and chemosensitizing function of Ai Du Qing (ADQ) formula made up of Hedyotis diffusa, Curcuma zedoaria (Christm.) Rosc., Astragalus membranaceus (Fisch.) Bunge, and Glycyrrhiza uralensis Fisch. Our findings revealed that ADQ significantly inhibited cell proliferation in both parental and chemo-resistant breast cancer cells, but with little cytotoxcity effects on the normal cells. Besides, ADQ was found to facilitate the G2/M arresting and apoptosis induction effects of paclitaxel. Network pharmacology and bioinformatics analysis further demonstrated that ADQ yielded 132 candidate compounds and 297 potential targets, and shared 22 putative targets associating with breast cancer chemoresponse. Enrichment analysis and experimental validation demonstrated that ADQ might improve breast cancer chemosensitivity via inhibiting caveolin-1, which further triggered expression changes of cell cycle-related proteins p21/cyclinB1 and apoptosis-associated proteins PARP1, BAX and Bcl-2. Besides, ADQ enhanced in vivo paclitaxel chemosensitivity on breast cancer. Our study not only uncovers the novel function and mechanisms of ADQ in chemosensitizing breast cancer at least partly via targeting caveolin-1, but also sheds novel light in utilizing network pharmacology in Chinese Medicine research. Frontiers Media S.A. 2018-10-02 /pmc/articles/PMC6176282/ /pubmed/30333750 http://dx.doi.org/10.3389/fphar.2018.01106 Text en Copyright © 2018 Wang, Yang, Zhang, Wang, Zheng, Li, Liu, Pan, Li, Huang, Zhang and Wang. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Wang, Neng
Yang, Bowen
Zhang, Xiaotong
Wang, Shengqi
Zheng, Yifeng
Li, Xiong
Liu, Shan
Pan, Hao
Li, Yingwei
Huang, Zhujuan
Zhang, Fengxue
Wang, Zhiyu
Network Pharmacology-Based Validation of Caveolin-1 as a Key Mediator of Ai Du Qing Inhibition of Drug Resistance in Breast Cancer
title Network Pharmacology-Based Validation of Caveolin-1 as a Key Mediator of Ai Du Qing Inhibition of Drug Resistance in Breast Cancer
title_full Network Pharmacology-Based Validation of Caveolin-1 as a Key Mediator of Ai Du Qing Inhibition of Drug Resistance in Breast Cancer
title_fullStr Network Pharmacology-Based Validation of Caveolin-1 as a Key Mediator of Ai Du Qing Inhibition of Drug Resistance in Breast Cancer
title_full_unstemmed Network Pharmacology-Based Validation of Caveolin-1 as a Key Mediator of Ai Du Qing Inhibition of Drug Resistance in Breast Cancer
title_short Network Pharmacology-Based Validation of Caveolin-1 as a Key Mediator of Ai Du Qing Inhibition of Drug Resistance in Breast Cancer
title_sort network pharmacology-based validation of caveolin-1 as a key mediator of ai du qing inhibition of drug resistance in breast cancer
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6176282/
https://www.ncbi.nlm.nih.gov/pubmed/30333750
http://dx.doi.org/10.3389/fphar.2018.01106
work_keys_str_mv AT wangneng networkpharmacologybasedvalidationofcaveolin1asakeymediatorofaiduqinginhibitionofdrugresistanceinbreastcancer
AT yangbowen networkpharmacologybasedvalidationofcaveolin1asakeymediatorofaiduqinginhibitionofdrugresistanceinbreastcancer
AT zhangxiaotong networkpharmacologybasedvalidationofcaveolin1asakeymediatorofaiduqinginhibitionofdrugresistanceinbreastcancer
AT wangshengqi networkpharmacologybasedvalidationofcaveolin1asakeymediatorofaiduqinginhibitionofdrugresistanceinbreastcancer
AT zhengyifeng networkpharmacologybasedvalidationofcaveolin1asakeymediatorofaiduqinginhibitionofdrugresistanceinbreastcancer
AT lixiong networkpharmacologybasedvalidationofcaveolin1asakeymediatorofaiduqinginhibitionofdrugresistanceinbreastcancer
AT liushan networkpharmacologybasedvalidationofcaveolin1asakeymediatorofaiduqinginhibitionofdrugresistanceinbreastcancer
AT panhao networkpharmacologybasedvalidationofcaveolin1asakeymediatorofaiduqinginhibitionofdrugresistanceinbreastcancer
AT liyingwei networkpharmacologybasedvalidationofcaveolin1asakeymediatorofaiduqinginhibitionofdrugresistanceinbreastcancer
AT huangzhujuan networkpharmacologybasedvalidationofcaveolin1asakeymediatorofaiduqinginhibitionofdrugresistanceinbreastcancer
AT zhangfengxue networkpharmacologybasedvalidationofcaveolin1asakeymediatorofaiduqinginhibitionofdrugresistanceinbreastcancer
AT wangzhiyu networkpharmacologybasedvalidationofcaveolin1asakeymediatorofaiduqinginhibitionofdrugresistanceinbreastcancer